Enter at least 3 characters
HOME > Therapy Areas > Rare Diseases
 

Chiesi are committed to finding breakthrough solutions to meet the unmet needs and improve the lives of patients with Rare Diseases.

 

Chiesi are industry pioneers in regenerative medicine, with the first ever stem-cell based therapy approved in the EU1 and the first to receive a positive NICE recommendation in England2

 

From drug discovery to patient access to medicine, The UK Rare Disease team will strive to work with patient organisations, clinicians and the wider healthcare system to help create a brighter future for patients with Rare Diseases.

 

References

  1. EMA. First stem-cell therapy recommended for approval in EU. EMA/786996/2014. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/12/news_detail_002239.jsp&mid=WC0b01ac058004d5c1. Access date: December 2018
  2. NICE. Holoclar for treating limbal cell deficiency after eye burns. Technology Appraisal Guidance 467. Available at https://www.nice.org.uk/guidance/ta467. Access date: December 2018

 

UK-CHI-1800066  December 2018